A biosimilar to Roche’s Rituxan, Truxima (rituximab) is indicated for blood cancer.
South Korea’s Celltrion Inc., has said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization to its Truxima (rituximab), a biosimilar to Roche’s Rituxan, which is indicated for blood cancer. The recommendation, issued last Friday is based on data from various studies that showed Truxima is bioequivalent to its reference drug Rituxan in safety and efficacy.
Market authorization usually follows the recommendation two to three months later, which was made by experts who reviewed efficacy and safety data of the drug. The EMA’s approval is equally effective in 27 European Union members and three European Economic Area countries - Norway, Iceland and Lichtenstein.
The recommendation for Truxima is applied to all indications of its reference drug, which include non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
Truxima was approved in Korea last month. The manufacturer aims to receive approval in Europe early next year and to plan to submit a New Drug Application (NDA) with the U.S. counterpart FDA in the first half of next year.
“We are working to launch Truxima in Europe with an anticipated milestone of regulatory approval early next year. The milestone will serve as an opportunity to reaffirm our vision to play as a first mover in the market and achieve 10 trillion won ($8.42 billion) in sales within 10 years and join the the top 10 list of global biotech companies,” said Celltrion president Kim Hyung-ki.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.